Greenland Mines Ltd (NASDAQ: GRML) has announced a series of strategic milestones that underscore its transition into a focused rare earths and critical minerals company. The company plans to spin off its biotechnology division in the fourth quarter of 2026, a move that will allow it to concentrate on its mining operations, particularly the development of the Sarfartoq neodymium-praseodymium (NdPr) rare earths project in southwest Greenland. This spin-off is part of a broader corporate restructuring that includes board changes and full compliance with Nasdaq listing requirements.
The Nasdaq has formally approved the company's application relating to its March 2026 transaction, resolving prior deficiencies and bringing Greenland Mines into full compliance with listing requirements. This approval is a critical step for the company, as it ensures continued listing on the exchange and provides a stable platform for its growth initiatives. The company also completed its acquisition of the Sarfartoq project on Sept. 1, following approval by the Government of Greenland. This acquisition is a cornerstone of Greenland Mines' strategy to build a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities.
An independent S-K 1300 Initial Assessment for the ST1 deposit at Sarfartoq has estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. These figures highlight the substantial economic potential of the project. Furthermore, Greenland Mines said that planned annual NdPr oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China, based on 2025 consumption levels, during each of the project's nine scheduled operating years. This positioning is significant given the global push for supply chain diversification in critical minerals, as NdPr is essential for permanent magnets used in electric vehicles and wind turbines.
In conjunction with these operational developments, Greenland Mines is reshaping its board. Riad El-Dada and Dr. Shalom Hirschman are stepping down, and capital markets veteran Jason Hawkins is joining the board. This change brings fresh expertise as Greenland Mines advances Sarfartoq and its Skaergaard palladium-gold-platinum project in southeast Greenland. The company's vision is to link Greenland resources with allied downstream jurisdictions and industrial infrastructure, creating a North Atlantic Critical Metals Corridor. This strategy aligns with broader geopolitical efforts to secure supply chains for critical minerals outside of dominant producing regions.
The spin-off of the biotech division, which includes Klotho's KLTO-202 primary indication for ALS, will allow shareholders to realize value in that segment while the mining division focuses on its core assets. This separation is expected to unlock value and provide clearer investment profiles for both entities. For Greenland Mines, the move sharpens its focus on becoming a leading supplier of rare earth elements, which are vital for the transition to clean energy and advanced technologies.
The company's progress on multiple fronts demonstrates its commitment to executing its strategic plan. With Nasdaq compliance achieved, the Sarfartoq acquisition completed, and a clear timeline for the biotech spin-off, Greenland Mines is positioning itself as a significant player in the critical minerals sector. The potential of the ST1 deposit, with its high NPV and IRR, underscores the value that could be realized as the project advances. As global demand for rare earth elements continues to grow, Greenland Mines' focused approach may offer investors a unique opportunity to participate in the critical minerals supply chain.
